Do most people keep weight off after stopping GLP-1 drugs?

What's this video probably claiming?

Based on the caption, @harpercarter67 appears to be pushing back against what she frames as an oversimplified narrative: that stopping semaglutide or tirzepatide automatically means rapid, complete weight regain. She seems to be referencing a real-world dataset of around 8,000 patients and suggesting those people maintained their weight after discontinuing a GLP-1 receptor agonist. The implicit argument is that the clinical trial data showing rapid regain doesn't necessarily reflect what happens outside controlled settings. That's a genuinely interesting question. It's also one where the creator, based on the caption alone, appears to be selectively interpreting the evidence in a way that needs serious scrutiny before it reaches the 1.4K people who watched this.

What does the science actually show?

The regain data from controlled trials is not subtle. The STEP 1 extension trial (Wilding et al., 2022, Diabetes, Obesity and Metabolism) followed participants who completed 68 weeks on 2.4mg semaglutide. One year after stopping, they had regained approximately two-thirds of their lost weight, averaging around 11.6% body weight return out of a prior 17.3% loss. Tirzepatide tells a similar story. The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed participants who discontinued tirzepatide after 36 weeks of treatment regained roughly 14 percentage points of body weight over the following 52 weeks, compared to a 5.5% additional loss in those who continued. These are not fringe results from small samples. The biology here is the point: GLP-1 receptor agonists work while you're taking them, and the hormonal and appetite-suppressing mechanisms they engage largely reverse when the drug clears your system.

Where does the social media noise diverge from clinical reality?

The creator's apparent reference to 8,000 real patients maintaining weight is likely pulling from observational or claims-database studies, which have significant confounding issues. Real-world data often captures patients who stopped GLP-1 drugs because they reached a goal and simultaneously adopted aggressive lifestyle changes, or who had bariatric surgery, or who were highly motivated outliers. That cohort is not representative. It's also worth flagging that "most kept their weight stable" is doing a lot of work as a phrase. Stable compared to what baseline? Over what follow-up period? Six weeks of stability after discontinuation is meaningless compared to a 12-month controlled follow-up. The pattern on TikTok in the #glp1girlies space tends toward reassurance, and reassurance about discontinuation risk is one of the more consequential things a creator can get wrong, because it affects whether people discuss a proper tapering or transition plan with their prescriber.

What should you actually know?

Weight regain after stopping GLP-1 medications is the expected physiological outcome for most people, not a rare exception. The degree of regain and the timeline vary depending on factors like how much weight was lost, duration of treatment, metabolic health status, and what lifestyle changes were made during treatment. Some patients do maintain meaningful weight loss after stopping, but the clinical literature does not support framing this as the typical outcome. If you are on semaglutide or tirzepatide and considering stopping, the conversation belongs with a prescriber, not a TikTok comment section. There are structured approaches to discontinuation and transition that exist precisely because the regain data is so consistent. The question of whether long-term or indefinite treatment is appropriate for you is a real clinical question with no universal answer.